Physician profile
David Steven Ryan
NPI 1629165618
$15,147.13
in general payments reported to CMS, 2019-2025
13 companies · $3,590 in 2025
The $3,590 reported for 2025 was more than what 79% of Orthopaedic Surgery providers received nationally (typical 2025 total: $569).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,096 · 2020: $5,885 · 2021: $191 · 2022: $307 · 2024: $79.27 · 2025: $3,590.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $3,500 · Food and Beverage: $169.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $3,500.00 |
| Food and Beverage | $168.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tracpatch Health, INC | $10,767.50 | 2019-2020 | |
| Shalby Advanced Technologies, INC. | $3,500.00 | 2025 | Consensus Hip System, Taperset Reduced Distal Profile, Cs2 Acet. Cup Sys. - Vitalite |
| Stryker Corporation | $183.30 | 2019-2020 | |
| Kerecis Limited | $169.18 | 2022 | |
| Horizon Therapeutics Plc | $117.48 | 2021-2022 | |
| Medacta USA, INC. | $83.39 | 2021 | |
| Fx Shoulder Solutions, INC | $79.27 | 2024 | |
| Anika Therapeutics, INC. | $68.78 | 2021 | |
| Cumberland Pharmaceuticals, INC. | $58.85 | 2022 | |
| Smith+Nephew, INC. | $53.25 | 2025 | Bioinductive Implant With Arthroscopic Delivery System - Medium |
| Bioventus LLC | $36.29 | 2025 | Durolane |
| Ortho Development Corporation | $17.56 | 2019 | |
| Orthofix Medical, INC. | $12.28 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$561,952.10 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Ryan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.